Skip to content

A study to compare liposomal iron with ferrous ascorbate in treatment of iron deficiency anaemia in children

Effect of Ferrous Ascorbate versus Liposomal iron on hemoglobin Concentration and Iron indices in 6 to 59 months age Children With Nutritional Iron-Deficiency Anemia: A Double blinded single centre Randomized clinical trial - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056246
Enrollment
96
Registered
2023-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D508- Other iron deficiency anemias

Interventions

Intervention1: Liposomal iron: liposomal iron syrup will be given at a dose of 1mg/kg/day once daily in night for 3 months Control Intervention1: ferrous ascorbate: ferrous ascorbate syrup will be giv

Sponsors

Namita Mishra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children in the age group 6 to 59 months with Iron Deficiency Anaemia as confirmed by hematological parameters

Exclusion criteria

Exclusion criteria: 1. Subjects with other causes of anemia(hemolytic anemia, bone marrow failure) as evidenced by clinical symptoms and signs and or laboratory values 2. Subjects with ongoing blood loss 3. Subjects who have received any iron therapy or blood transfusion in the past 3 months 4. Subjects with disease interfering with iron absorption e.g. Inflammatory bowel disease, celiac disease, bowel surgery, chronic gastrointestinal infection 5. Subjects with serious chronic medical conditions like chronic kidney disease, congenital heart disease, and chronic lung disease. 6. Subjects with prior history of allergy to iron preparations

Design outcomes

Primary

MeasureTime frame
Rise in hemoglobin levels from baseline in gram per deciliterTimepoint: 0, 4 and 12 weeks

Secondary

MeasureTime frame
Adherence to medicine in both groups as measured by volume of unused drug brought in follow up visit.Timepoint: 0, 4 and 12 weeks;Change in mean corpuscular volume, corrected reticulocyte count, serum iron, serum ferritin, total iron binding capacity and transferrin saturation from baselineTimepoint: 0, 4 and 12 weeks

Countries

India

Contacts

Public Contactnamita mishra

AIIMS Hospital

namitam23@gmail.com9450789623

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026